- About Us
- Services & Solutions
- Technologies
- Discovery
- Reagent Materials Generation
- Monoclonal Antibody Discovery
- Bispecific & Multispecific Antibody Generation
- Lead Optimization
- In Vitro Lead Characterization
- In Vivo Lead Characterization
- Other Molecular Modalities
- IND Filing Support
- Protein Sciences
- Antibody Production
- Protein Production
- Protein Characterization
- Protein Sciences
- Mammalian
- Microbial
- mRNA
- Viral Vaccines
- WuXi XDC – Bioconjugation
- Testing
- Sustainability
- Careers
- Investors
- News & Resources
WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & SolutionsAbout Us
- SustainabilityAbout Us
- CareersAbout Us
- InvestorsAbout Us
- News & ResourcesAbout Us
Scientific Poster Download
Poster modified on 17/10/2023
A Novel Conjugation Technology for Native Antibodies that Generates ADCs with a Narrowly Distributed DAR
Qirui Fan, Lin Zhang, Ao Ji, Xudong Dai, Jiawei Lu, Laisen Wang, Yanjie Zhao, Zekun Wang
WuXi XDC (Shanghai), Co. Ltd.
Conventional lysine- or cysteine-based conjugation results in heterogeneous ADC products due to a wide drug-to-antibody ratio(DAR) distribution. Over the last decade, many site-specific conjugation technologies have been developed to address this issue, yet the improved homogeneity usually comes at a cost. To address these issues, WuXi XDC developed WuXiDAR2™, WuXiDAR4™ and WuXiDAR6™, collectively referred to as the WuXiDARx technology platform.
This scientific poster was originally presented during the 2023 World ADC Conference in San Diego
Discuss This Poster
To discuss the data in this poster, please complete the form on the following page to connect with our experts.